Emerging treatments
New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM et al. Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM et al. Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
Genomic complexity of multiple myeloma and its clinical implications. Manier S et al. Nat Rev Clin Oncol. 2016 Aug 17. doi: 10.1038/nrclinonc.2016.122. [Epub ahead of print]. Baseline characteristics, chromosomal alterations and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Merz M et al. Am J Hematol. 2016 Aug 10. doi: 10.1002/ajh.24533. [Epub ahead of print]. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple…
DetailsIs Maintenance Therapy for Everyone? Nooka AK et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S139-44. doi: 10.1016/j.clml.2016.02.011. How to Think About Risk in Myeloma. Krishnan A. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S135-8. doi: 10.1016/j.clml.2016.02.015. Clonal Evolution in Multiple Myeloma. Fakhri B et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S130-4. doi: 10.1016/j.clml.2016.02.025. Concise review: Treatment of multiple myeloma in the very elderly: How do novel agents fit in? Kint N et al. J…
DetailsCost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Chalayer E et al. Thromb Res. 2016 Aug 10;145:119-125. doi: 10.1016/j.thromres.2016.08.008. [Epub ahead of print]. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Marchesi F et al. Bone Marrow Transplant. 2016 Aug 15. doi:…
DetailsChemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles. Hall J et al. Thromb Res. 2016 Aug 17;146:20-22. doi: 10.1016/j.thromres.2016.08.017. [Epub ahead of print]. Diarrhea in Multiple Myeloma: A Review of the Literature. Faiman B et al. Clin J Oncol Nurs. 2016 Aug 1;20(4):E100-5. doi: 10.1188/16.CJON.E100-E105. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. Castillo…
DetailsThe impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Chakraborty R et al. Bone Marrow Transplant. 2016 Aug 22. doi: 10.1038/bmt.2016.214. [Epub ahead of print]. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Kouroukis CT et al. Curr Oncol. 2016 Aug;23(4):e409-30. doi: 10.3747/co.23.3137. Epub 2016 Aug 12. Mobilization of autologous…
DetailsA revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…
DetailsThe International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response…
DetailsClinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis. Wei B et al. Onco Targets Ther. 2016 Jul 1;9:4015-22. doi: 10.2147/OTT.S102733. eCollection 2016. RGS1 expression is associated with poor prognosis in multiple myeloma. Roh J et al. J Clin Pathol. 2016 Jul 21. pii: jclinpath-2016-203713. doi: 10.1136/jclinpath-2016-203713. [Epub ahead of print]. Diagnostic performances of M-protein tests according to the clinical presentations…
DetailsRationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Merlini G et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.191. [Epub ahead of print]. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Hogan JJ et al. Clin J Am Soc Nephrol. 2016 Jul 14. pii:…
Details